Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session 3

5477 - Impact of sarcopenia in patients with metastatic melanoma treated with immunotherapy


30 Sep 2019


Poster Display session 3


Tumour Site



Maria Grazia Vitale


Annals of Oncology (2019) 30 (suppl_5): v533-v563. 10.1093/annonc/mdz255


M.G. Vitale1, D. Basile2, E. Bertoli1, M. Giavarra1, G. Pelizzari2, L. Palmero1, D. Zara1, G. Targato1, G. Pascoletti3, M. Cinausero3, E. Poletto3, D. Iacono3, F. Puglisi2, G. Fasola3, A.M. Minisini3

Author affiliations

  • 1 Department Of Oncology, Azienda Sanitaria Universitaria Integrata Di Udine; Department Of Medicine (dame), University of Udine, 33100 - Udine/IT
  • 2 Department Of Medicine (dame), University Of Udine; Department Of Medical Oncology And Cancer Prevention, IRCCS CRO National Cancer Institute, 33081 - Aviano/IT
  • 3 Department Of Oncology, Azienda Sanitaria Universitaria Integrata di Udine, 33100 - Udine/IT


Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 5477


High BMI is associated with better survival in metastatic melanoma patients (MM pts), while sarcopenia is linked to poorer outcome in pts with stage III. The aim of this study was to examine the prognostic impact of body-mass index (BMI), baseline sarcopenia, loss of skeletal muscle mass (LSMM) on overall survival (OS) in MM pts who received immunotherapy (IT).


The retrospective series included 42 consecutive MM pts (Jan 2011-Dec 2018) treated with IT in a single referral center. Sarcopenia was defined according to Prado’s criteria. Skeletal muscle index (SMI) was calculated as cross-sectional-area of muscle (cm2), using CT-scan, at the L3 level divided by the square of the height (m2). Early LSMM, during IT, was defined as a decrease in SMI > =10% from baseline at first evaluation. BMI was calculated as weight (kg) divided by the square of height (m2) and categorized according to standard WHO definitions. Weight loss was analyzed as continuous variable.


At baseline, 27 pts (64,3%) were male, 26 pts (61.9%) were < 70 years and 31 pts (73.8%) had ECOG PS = 0. Overall, 26 patient (61.9%) had LDH  =25. Out of 42 pts, 30 (71.4%) had a CT-scan at first evaluation, and 30% of them had an early LSMM. Median OS was 11.38 months. Both in univariate and multivariate analysis, ECOG PS > =1, and early LSMM > =10% were significantly associated with worse OS. Conversely, pts with weight loss had better OS (Table).Table:


OS univariate analysisOS multivariate analysis
FactorsHRp95% Confidence IntervalHRp95% Confidence Interval
PS ECOG³13.020.01(1.29-7.08)3.990.043(1.04-15.31)
Weight loss0.880.03(0.78-0.98)0.850.02(0.74-0.97)
Early LSMM  > =10%4.240.006(1.50-11.97)3.090.04(1.04-9.22)


Early LSMM > =10% and ECOG PS > =1 may negatively influence the outcome of MM pts treated with IT. Further prospective studies are needed to confirm these data.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

Maria Grazia Vitale.


Has not received any funding.


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.